<DOC>
	<DOCNO>NCT01885819</DOCNO>
	<brief_summary>Autologous stromal vascular fraction ( SVF ) inject 8 10 day extraction safe useful procedure induce remission RA patient resistant standard DMARD therapy .</brief_summary>
	<brief_title>Autologous Adipose Tissue Stromal Vascular Fraction Cells Rheumatoid Arthritis</brief_title>
	<detailed_description>The propose study ass primarily safety secondary efficacy endpoint autologous stromal vascular fraction ( SVF ) cell administer 20 patient disease modifying antirheumatic drug ( DMARD ) -resistant Rheumatoid Arthritis ( RA ) nonresponsive least one course one DMARD select group comprising : gold salt , leflunomide , methotrexate , hydroxychloroquine . The primary objective safety define freedom treatment associate adverse event period one year . The secondary objective efficacy include evaluation baseline month 1 , 2 , 3 6 efficacy endpoint CRP , ESR , anti-citrulline antibody , RF , Quality Life Questionnaire , 28-joint disease activity score ( DAS28 ) , European League Rheumatism ( EULAR ) response criterion immunological parameter .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Age old 18 year ability understand plan treatment . Patients either gender RA duration 6 72 month define presence least three follow criterion : 6 painful , 2 swollen joint , morning stiffness least 45 minute ( average week prior entry ) , erythrocyte sedimentation rate ( ESR ) least 28 mm . Nonresponsive least one course one DMARD select group comprising : gold salt , leflunomide , methotrexate , hydroxychloroquine . Secondline agent discontinue least 4 week prior entry . Able tolerate ALL study procedure Able give inform Consent Negative HcG serum pregnancy test Hematocrit ≥ 28.0 % , White Blood Cell count ≤ 14,000 , Platelet count ≥ 50,000 , Life expectancy 6 month opinion investigator Serum bilirubin , ALT , AST 2.5 time upper level normal . Controlled blood pressure ( systolic blood pressure ≤140 diastolic blood pressure ≤90 mmHG ) establish antihypertensive therapy necessary prior entry study Patient receive stable , standard medical therapy least one month new medication treat disease introduce last month . Preexisting condition ( e.g . thromboembolic risk , diabetes , hypercholesterolemia ) adequately control opinion investigator Fertile patient ( male female ) must agree use appropriate form contraception participate study . Female pregnant nursing , child bear potential use reliable birth control method , intend become pregnant tenure study . History prior radiation exposure oncological treatment . History Bone Marrow Disorder ( especially NHL , MDS ) History abnormal bleeding clotting . History Liver Cirrhosis . End stage renal disease ( Creatinine ≤ 3.0 mg / dl ) and/or dialysis Active clinical infection treat antibiotic one week enrollment Inability unwillingness comply treatment protocol , followup , research test , give consent . History lifethreatening arrhythmia , except automate implantable cardioverter defibrillator ( AICD ) implant Life expectancy &lt; 6 month due concomitant illness Known cancer undergo treatment ; chemotherapy and/or radiotherapy Patients receive treatment hematopoietic growth factor ( e.g. , EPO , GCSF ) Patients stop anticoagulation therapy ( warfarin ) 72hrs prior infusion Patients stop antiplatelet therapy ( clopidogrel ) 7 day prior infusion Prior admission substance abuse Body Mass Index ( BMI ) 40 kg/m2 great Patient receive experimental medication participate another clinical study within 30 day sign informed consent In opinion investigator sponsor , patient unsuitable cellular therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Adipose stromal vascular fraction</keyword>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>adult stem cell</keyword>
</DOC>